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Emergence of Multidrug-Resistant Campylobacter Species Isolates with a
Horizontally Acquired rRNA Methylase
Abstract
Antibiotic-resistant Campylobacter constitutes a serious threat to public health, and resistance to macrolides
is of particular concern, as this class of antibiotics is the drug of choice for clinical therapy of
campylobacteriosis. Very recently, a horizontally transferrable macrolide resistance mediated by the rRNA
methylase gene erm(B) was reported in a Campylobacter coli isolate, but little is known about the
dissemination of erm(B) among Campylobacter isolates and the association of erm(B)-carrying isolates with
clinical disease. To address this question and facilitate the control of antibiotic-resistant Campylobacter, we
determined the distribution of erm(B) in 1,554 C. coli and Campylobacter jejuni isolates derived from food-
producing animals and clinically confirmed human diarrheal cases. The results revealed that 58 of the
examined isolates harbored erm(B) and exhibited high-level resistance to macrolides, and most were recent
isolates, derived in 2011-2012. In addition, the erm(B)-positive isolates were all resistant to fluoroquinolones,
another clinically important antibiotic used for treating campylobacteriosis. The erm(B) gene is found to be
associated with chromosomal multidrug resistance genomic islands (MDRGIs) of Gram-positive origin or
with plasmids of various sizes. All MDRGIs were transferrable to macrolide-susceptible C. jejuni by natural
transformation under laboratory conditions. Molecular typing of the erm(B)-carrying isolates by pulsed-field
gel electrophoresis (PFGE) and multilocus sequence typing (MLST) identified diverse genotypes and
outbreak-associated diarrheal isolates. Molecular typing also suggested zoonotic transmission of erm(B)-
positive Campylobacter. These findings reveal an emerging and alarming trend of dissemination of erm(B) and
MDRGIs in Campylobacter and underscore the need for heightened efforts to control their further spread.
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Antibiotic-resistant Campylobacter constitutes a serious threat to public health, and resistance to macrolides is of particular
concern, as this class of antibiotics is the drug of choice for clinical therapy of campylobacteriosis. Very recently, a horizontally
transferrable macrolide resistance mediated by the rRNAmethylase gene erm(B) was reported in a Campylobacter coli isolate,
but little is known about the dissemination of erm(B) among Campylobacter isolates and the association of erm(B)-carrying iso-
lates with clinical disease. To address this question and facilitate the control of antibiotic-resistant Campylobacter, we deter-
mined the distribution of erm(B) in 1,554 C. coli and Campylobacter jejuni isolates derived from food-producing animals and
clinically confirmed human diarrheal cases. The results revealed that 58 of the examined isolates harbored erm(B) and exhibited
high-level resistance to macrolides, andmost were recent isolates, derived in 2011-2012. In addition, the erm(B)-positive isolates
were all resistant to fluoroquinolones, another clinically important antibiotic used for treating campylobacteriosis. The erm(B)
gene is found to be associated with chromosomal multidrug resistance genomic islands (MDRGIs) of Gram-positive origin or
with plasmids of various sizes. All MDRGIs were transferrable to macrolide-susceptible C. jejuni by natural transformation un-
der laboratory conditions. Molecular typing of the erm(B)-carrying isolates by pulsed-field gel electrophoresis (PFGE) andmul-
tilocus sequence typing (MLST) identified diverse genotypes and outbreak-associated diarrheal isolates. Molecular typing also
suggested zoonotic transmission of erm(B)-positive Campylobacter. These findings reveal an emerging and alarming trend of
dissemination of erm(B) andMDRGIs in Campylobacter and underscore the need for heightened efforts to control their further
spread.
Campylobacter is the leading bacterial cause of food-borne ill-nesses worldwide and primarily causes gastroenteritis (1). For
clinical treatment of campylobacteriosis, fluoroquinolones and
macrolides are often prescribed (2); however, the resistance of
Campylobacter to clinically important antibiotics is increasingly
reported. Indeed, the 2013 CDC report identified antibiotic-resis-
tant Campylobacter as a serious antibiotic resistance threat in the
U.S. (http://www.cdc.gov/drugresistance/threat-report-2013/pdf
/ar-threats-2013-508.pdf). Due to the increasing prevalence of
fluoroquinolone-resistant Campylobacter worldwide (3–5), mac-
rolides are now considered the drug of choice for therapeutic pur-
poses (2, 6). Thus, development and spread of macrolide resis-
tance in Campylobacter will significantly limit the options for
clinical treatment.
Historically, macrolide resistance inCampylobacter has been at
a low level of incidence and ismainlymediated by pointmutations
in the 23S rRNA or in the rplD and rplV genes encoding 50S
ribosomal subunit proteins L4 and L22. The mutations occur at
low frequencies and incur fitness costs in Campylobacter (6–9),
partly explaining the low prevalence of macrolide resistance in
Campylobacter. rRNAmethylases, which represent major mecha-
nisms for macrolide resistance in other bacterial organisms (10),
were not identified inCampylobacter until recently. A recent work
by our group reported the identification of a Gram-positive
erm(B) gene in a single porcine Campylobacter coli isolate (11),
which carried no mutations in the 23S rRNA or in the rplD and
rplV genes. erm(B) encodes a rRNAmethylase andmediates high-
level macrolide resistance (MIC 512 g/ml) in Campylobacter,
and it can be transferred between Campylobacter jejuni and Cam-
pylobacter coli via natural transformation (11). This was the first
identification of a horizontally transferrable macrolide resistance
mechanism in thermophilic Campylobacter spp.
The identification of a horizontally transferrable erm(B) inCam-
pylobacter is alarming, as the gene confers high-level resistance to
macrolides and can be disseminated by horizontal gene transfer.
However, nothing is known about the distribution of erm(B) in
Campylobacter and the association of erm(B)-carrying Campylo-
bacter strains with clinical disease. To answer this question and
facilitate the control of antibiotic-resistant Campylobacter, we in-
vestigated the incidence of erm(B) in Campylobacter isolates de-
rived from both human diarrheal cases and food-producing ani-
mals, determined the gene environments surrounding erm(B),
and characterized the erm(B)-positive isolates by molecular typ-
ing methods.
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MATERIALS AND METHODS
Campylobacter strains, growth conditions, and antimicrobial suscepti-
bility testing.A total of 1,554Campylobacter isolates (1,157C. coli and 397
C. jejuni isolates) were analyzed in this study. Detailed information on
isolates is listed in Table S1 in the supplementalmaterial. These include 75
human isolates, 789 swine isolates, 433 chicken isolates, 227 duck isolates,
and 30 isolates from chicken carcasses. The previously identified erm(B)-
carrying C. coli ZC113 of swine origin was included as a reference in this
study (11). The 75 human C. coli isolates were from the retrospective
collection of Chinese Centers for Disease Control and Prevention (CDC,
Beijing, China) and were obtained during 2001–2011 from clinically con-
firmed gastroenteritis in four different provinces or cities. Due to the lack
of a surveillance system for the Campylobacter spp. in patients with diar-
rhea or gastrointestinal disease in hospitals in China, clinicalCampylobac-
ter isolates were available from only a few hospitals, which had a collab-
orative relationship with China CDC. All patients have not been
administered macrolides, but whether these patients had taken macro-
lides by themselves at home was unknown. The swine isolates were cul-
tured from feces, and the chicken and duck isolates were cultured from
cloacal swabs during 2008–2012 from Shandong, Ningxia, and Guang-
dong provinces under the routine program of surveillance for antimicro-
bial resistance in bacteria of animal origin (12, 13). Although information
on antimicrobial usage for the herds/flocks from which the isolates were
obtained was not available, the antibiotic usage records for some of the
farms inwhich the isolateswas collected indicated thatmacrolides, such as
tylosin, spiramycin, and erythromycin, had been commonly used for cur-
ing or preventing bacterial infections (14). In addition, 30 Campylobacter
isolates were cultured fromwhole chicken carcasses, which were collected
after processing but before distribution in two slaughterhouses located in
geographically separated regions of Shandong province in May 2011. All
of the above-mentioned isolates were obtained based on one isolate per
animal. In laboratory, all these Campylobacter isolates were grown on
Mueller-Hinton agar (MHA; Sigma-Aldrich, MO, USA) at 42°C under
microaerobic conditions (5%O2, 10% CO2, and 85%N2). The Campylo-
bacter-specific growth supplements and selective agents (Oxoid, Hamp-
shire, United Kingdom) were added to the media when needed. The iso-
lates were further confirmed by PCR as C. coli or C. jejuni as previously
described (15). The standard agar dilution method recommended by
Clinical and Laboratory Standards Institute (CLSI; 2008) was used to
determine the MICs of various antibiotics in the Campylobacter isolates
(16). C. jejuni ATCC 33560 was used as the quality control strain.
PCR identificationof erm(B) in variousCampylobacter isolates, and
determinationof its locationandgenetic environments.The erm(B)was
identified in various Campylobacter isolates by PCR and sequencing. An
421-bp amplicon of erm(B) was produced by using the primers erm(B)-F
(5=-GGGCATTTAACGACGAAACTGG) and erm(B)-R (5=-CTGTGGT
ATGGCGGGTAAGT), which were designed according to the conserved
regions of the erm(B) genes found in C. coli ZC113, Enterococcus faecium
(accession no. JN899585), Streptococcus pneumoniae (X52632), and Lac-
tobacillus reuteri (AY082384). A modified random primer-walking strat-
egy as previously described was performed using primers which were
complementary to locations inside erm(B) for the sequence of entire open
reading frame (ORF) of this gene (17). To determine whether erm(B) was
localized in plasmids or on the chromosome, we analyzed the erm(B)-
positiveCampylobacter isolates by S1 nuclease pulsed-field gel electropho-
resis (PFGE) and Southern blotting. Whole cells of the isolates were em-
bedded in agarose gel plugs and digested with S1 nuclease (TaKaRa,
Dalian, China), and the DNA was separated by PFGE as described previ-
ously (18). For Southern blotting, the 421-bp PCR product of erm(B) was
used as the probe for hybridization. The probe was labeled with a digoxi-
genin (DIG) High Prime I DNA labeling and detection starter kit (Roche
Diagnostics, Mannheim, Germany). Hybridization was performed at
44°C for 14 h. Membranes were washed twice at room temperature (22 to
25°C) with 2 SSC (1 SSC is 0.15MNaCl plus 0.015M sodium citrate)
and 0.1% SDS for 5 min and twice at 68°C with 0.5 SSC and 0.1% SDS
for 15 min. DIG was detected with specific antibodies using a DIG High
Prime I DNA labeling and detection starter kit according to the protocol
of the supplier. The genetic environments of erm(B) in 26 C. coli isolates
that harbored a chromosomally carried erm(B) were determined by using
a long-range PCRwith primers cadf-F2 and pfo-R2 or amodified random
primer-walking sequencing strategy as described previously (15, 17).
Genotyping. Multilocus sequence typing (MLST) for Campylobacter
was performed following the method described previously (19). The al-
lelic profiles and the sequence types were generated by blasting the Cam-
pylobacter sequences in the MLST database (http://www.pubmlst.org
/campylobacter). PFGE was performed using a CHEF-DR III apparatus
(Bio-Rad Laboratories, Hercules, CA, USA), according to the rapid pro-
tocol for Campylobacter (20), and Salmonella H9812 was used as the ref-
erence marker (digested with XbaI), while allCampylobacter isolates were
digested with SmaI. The dendrograms were constructed from the PFGE
data by the unweighted pair group method with arithmetic average
(UPGMA) with the Dice coefficient using InfoQuest FP software, version
4.5 (Bio-Rad Laboratories, USA).
Plasmid typing. Plasmid typing was performed for the C. coli isolates
that harbored a plasmid-borne erm(B) gene (Table 1). Since no Campy-
lobacter-specific plasmid typing methods are available (21, 22), the in-
compatibility groups were characterized using the replicon typing meth-
ods for Enterobacteriaceae as previously described (23, 24).
Transfer of macrolide resistance by natural transformation or elec-
trotransformation.Macrolide resistance inC. coli isolates was transferred
to the macrolide-susceptible C. jejuni strain NCTC 11168 or 81-176 by
natural transformation, which was performed according to the method
described by Wang and Taylor (25). We also determined if these erm(B)
gene-carrying plasmids in C. coli isolates could be transferred to C. jejuni
NCTC 11168 or 81-176 and C. coli ATCC 33559 using both the natural
transformation and electroporation methods (26). The transformants
were selected on MH agar plates containing erythromycin (10 g/ml).
The transformation without donor DNA was used as a negative control.
All copies of the 23S rRNA gene of the transformants were sequenced to
confirm lack of mutations in this gene in the transformants (27). More-
over, to confirm the transfer of the erm(B) gene and other resistance genes
to the transformants, long-range PCR assays were conducted in the trans-
formants using primers cadf-F2 and pfo-R2 to amplify the region between
cadF and cj1476c genes (15), and primers rdxA-F (5=-GGTATTTTGGCT
CGTGAGCTTG) and ACE-R (5=-GCATATGAAGACAAGGGAGCT) to
amplify the region between the nfsB and aac genes.
Nucleotide sequence accession numbers. The erm(B)-carrying seg-
ments in various isolates have been deposited in GenBank, and their ac-
cession numbers are KC876748 (ZP-GX-1), KC876749 (DZB4),
KC876750 (HN-CCD07046), KC876751 (SH-CCD11C073), and
KC876752 (SH-CCD11C365).
RESULTS AND DISCUSSION
Presence of erm(B) in Campylobacter isolates. In total, 1,554
Campylobacter isolates (1,157 C. coli and 397 C. jejuni isolates)
were examined in this study, including 75 isolates from human
diarrheal cases and the rest from swine, chicken, and duck species
(see Table S1 in the supplemental material). Among the isolates
examined, 58 were positive for erm(B), including 57 C. coli and 1
C. jejuni isolates (Table 1). Ten of the erm(B)-positive isolates
were from humans, 32 from swine, 14 from chicken, and 2 from
duck, and the percentage of erm(B)-positive Campylobacter iso-
lates in each of the sources is indicated in Table S2 in the supple-
mentalmaterial. TheMIC results indicated that all 58 isolateswere
resistant to erythromycin, clindamycin, ciprofloxacin, and tetra-
cycline, and 39 of them (67%) were also resistant to gentamicin
(Table 1). Most of the 58 isolates showed an erythromycinMIC of
512 g/ml. Twenty-two of the 58 (38%) erm(B)-positive Cam-
pylobacter strains harbored the A2075G (equivalent to A2059G in
Wang et al.
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TABLE 1 Characteristics of the 58 erm(B)-positive Campylobacter isolates identified in this study
Isolatea Hostb
Province/
cityc Sample
Yr of
isolation
Mutation in
23S rRNAg
Location of
erm(B)d
MDRGI
typee
MIC (g/ml)f
CIP
(4)
ERY
(32)
CLI
(8)
GEN
(8)
TET
(16)
CHL
(32)
ZC113 (reference strain) S SD Feces 2008 — C I 32 512 256 128 128 4
C179b C GD Feces 2012 — C — 32 >512 256 1 256 4
YC74 S NX Feces 2009 A2075G P 64 128 16 >256 128 4
ZP-GX-1 C SD Carcass 2011 — C III 16 128 >256 256 512 8
ZP-GX-5 C SD Carcass 2011 — C III 32 512 128 128 512 8
ZP-GX-8 C SD Carcass 2011 — C III 32 512 128 128 512 8
ZP-GX-12 C SD Carcass 2011 — C III 32 512 128 128 512 8
ZP-GX-14 C SD Carcass 2011 — C III 64 512 128 128 512 8
ZP-GX-20 C SD Carcass 2011 — C III 32 512 128 128 512 8
ZP-GX-26 C SD Carcass 2011 — C III 64 512 128 128 256 8
ZP-GX-28 C SD Carcass 2011 — C III 16 128 >256 128 512 8
ZP-GX-35 C SD Carcass 2011 — C III 32 512 128 128 512 8
ZP-GX-36 C SD Carcass 2011 — C III 64 512 128 128 512 8
ZP-GX-37 C SD Carcass 2011 — C III 64 512 128 128 256 8
LH-GX-14 C SD Carcass 2011 — C III 64 256 128 128 256 4
DH46a D SD Feces 2012 — C — 64 512 256 >256 128 16
DH67 D SD Feces 2008 — C III 64 512 256 256 128 64
DZ5 S SD Feces 2012 A2075G C — 32 512 32 1 512 8
DZ50 S SD Feces 2008 A2075G C, P — 32 512 8 256 256 4
DZ14a S SD Feces 2012 A2075G P 16 512 32 >256 128 4
DZB1 S SD Feces 2012 A2075G P 32 512 16 1 512 4
DZB4 S SD Feces 2012 — C II 32 256 256 >256 128 4
DZB5 S SD Feces 2012 A2075G P 32 512 32 >256 512 8
DZB7 S SD Feces 2012 — C — 64 64 16 2 64 4
DZB12 S SD Feces 2012 — C I 32 512 256 >256 128 8
DZB41 S SD Feces 2012 A2075G P 16 512 32 1 512 4
158 C SD Feces 2008 — C III 32 32 >256 128 128 2
TH34 S GD Feces 2012 A2075G P 32 128 32 1 128 16
TH45 S GD Feces 2012 — P 32 >512 32 >256 512 16
TH48 S GD Feces 2012 A2075G P 16 >512 64 256 128 32
TH62 S GD Feces 2012 A2075G P 16 >512 32 1 512 8
TH74 S GD Feces 2012 A2075G P 16 >512 64 1 512 32
TH80 S GD Feces 2012 A2075G P 32 >512 32 >256 32 32
TH96 S GD Feces 2012 A2075G P 8 >512 64 4 128 32
TH117 S GD Feces 2012 A2075G C — 32 >512 128 256 512 8
TH119 S GD Feces 2012 A2075G P 16 >512 64 1 32 4
52-3b S GD Feces 2012 A2075G P 32 >512 32 1 128 32
84a S GD Feces 2012 A2075G C — 16 512 32 1 128 4
08-23 S GD Feces 2012 A2075G C — 32 >512 32 >256 64 16
08-120 S GD Feces 2012 A2075G P 8 >512 32 2 128 4
10-5-18 S GD Feces 2012 A2075G P 8 >512 64 256 128 32
10-7-1a S GD Feces 2012 — P 8 >512 64 1 512 4
10-7-1c S GD Feces 2012 — P 8 >512 32 1 512 4
10-13-6a S GD Feces 2012 A2075G P 32 >512 32 256 128 8
10-33-66 S GD Feces 2012 A2075G P 32 >512 32 256 128 64
JW16 S NX Feces 2012 — P 32 32 32 4 64 4
LWC2 S NX Feces 2012 — P 8 512 32 1 128 2
LWD21 S NX Feces 2012 — P 16 32 16 0.5 32 4
LWD84 S NX Feces 2012 — P 32 64 8 2 128 4
HN-CCD07046 H HN Stool 2007 — C IV 128 128 256 256 128 32
SH-CCD11C073 H SH Stool 2011 — C V 32 128 256 128 512 32
SH-CCD11C226 H SH Stool 2011 — C III 64 512 256 >256 128 64
SH-CCD11C287 H SH Stool 2011 — C VI 256 512 256 256 128 64
SH-CCD11C365 H SH Stool 2011 — C VI 256 512 256 128 512 16
SH-CCD11C416 H SH Stool 2011 — C VI 64 128 256 128 512 16
SH-CCD11C419 H SH Stool 2011 — C III 64 512 256 128 128 32
SH-CCD11C490 H SH Stool 2011 — C VI 128 128 256 256 128 64
SH-CCD11C518 H SH Stool 2011 — C VI 256 512 256 256 512 64
SH-CCD11C682 H SH Stool 2011 — C VI 64 128 256 128 128 16
a All but one are C. coli, and C179b is C. jejuni. The erm(B)-carrying isolate C. coli ZC113 identified in the previous study (11) is included as a reference.
b S, swine; C, chicken; D, duck; H, human.
c SD, Shandong; NX, Ningxia; GD, Guangdong; HN, Henan; SH, Shanghai.
d erm(B) is on the chromosome (C), the plasmid (P), or both (C, P).
e —, the genetic environment of erm(B) in the chromosome could not be determined by the primer walking strategy used in this study.
f CIP, ciprofloxacin; ERY, erythromycin; CLI, clindamycin; GEN, gentamicin; TET, tetracycline; CHL, chloramphenicol. Numbers in parentheses are MIC breakpoints. The MICs
over the breakpoint are in bold.
g —, no mutations detected in 23S rRNA gene.
erm(B) in Campylobacter
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E. coli) mutation in 23S rRNA, and these isolates exhibited no
significant difference (P  0.05) in the MICs of erythromycin
compared with the other 36 isolates that had no mutation in the
target gene (Table 1). Sequencing of the PCR products revealed
three variants of erm(B) among the 58 isolates with lengths of 738
bp (n  34), 753 bp (n  21), and 765 bp (n  3). PFGE and
Southern blotting revealed that 33 (57%) isolates, including theC.
jejuni isolate C179b, carried erm(B) on the chromosome, while 24
(41%) isolates harbored erm(B) on plasmids of various sizes (Ta-
ble 1; representative results are shown in Fig. S1 in the supplemen-
tal material).
Notably, most (53/58) of the erm(B)-positive Campylobacter
isolates were obtained in recent years (2011-2012) (see Table S1 in
the supplemental material). Among the 720 isolates collected
from 2007 to 2009, 5 (0.7%) were positive with erm(B), while 53
(6.4%) of the 829 isolates collected during 2011-2012 were posi-
tive for erm(B). This finding suggests the recent emergence and a
rising trend for erm(B)-carrying Campylobacter isolates in China.
Genetic environments of the erm(B) gene on the chromo-
some of C. coli isolates.We further determined the genetic envi-
ronments of erm(B) in 26 C. coli isolates that harbored a chromo-
somally carried erm(B) gene. In all cases, erm(B) was associated
with multidrug resistance genomic islands (MDRGIs), which
were inserted between cadF and CCO1582 (19 isolates) or in the
aac gene, located between nfsB and cinA (7 isolates) (Fig. 1). The
MDRGIs were classified into six types (designated I to VI) accord-
ing to their gene contents and insertion sites on chromosome, and
the previously identified MDRGI in ZC113 was designated type I
(Table 1; Fig. 1). Types I to IV were bordered by cadF and
CCO1582, while types V and VI were inserted in the aac gene. The
GC contents of theMDRGIs ranged from 34.3% to 37.3%, higher
than that (31.4%) of the genome ofC. coliRM2228. Among them,
type III was the most common and was observed in 16 isolates
originated from both human and other animal species. Types IV,
V, and VI were detected only in the human isolates, while types I
and II were observed only in the swine isolates (Table 1).
Most of the ORFs in theMDRGIs are either identical or90%
identical to their orthologs inGram-positive bacteria (see Table S3
in the supplemental material), implying that all erm(B)-carrying
MDRGIs in Campylobacter were derived from Gram-positive or-
igins. The orf7 gene encodes a conserved hypothetical protein that
shares 95.8 to 97.1% amino acid (aa) identity to a hypothetical
ORF in Clostridium difficileNAP08 (ZP_06892641) and is located
immediately upstream of erm(B) in all but type II MDRGIs (Fig.
2). For type II, orf9 is inserted between orf7 and erm(B). The de-
duced amino acid sequence of orf9 showed 64.7% amino acid (aa)
identity (86/133) to the fosfomycin resistance protein FosX of
Listeria monocytogenes (YP_005962817). The twoORFs ( and )
immediately downstream of erm(B) were conserved in types I, II,
III, and VI. The gene encodes 71 aa and shares 97.2% (69/71) aa
identity to the gene in Streptococcus agalactiae (ZP_22245542).
The  gene encodes 95 aa and shows 98.8% (89/90) aa identity to
the corresponding region of  in Streptococcus pyogenes
(YP_232758). Regarding the other resistance genes, the aminogly-
coside resistance gene aadE, located downstream of erm(B), was
highly conserved (99.9% nucleotide identity) in all MDRGIs,
FIG 1 Chromosomal organization and comparison of six different types (I to VI) ofMDRGIs in erm(B)-positiveC. coli isolates. erm(B) is in red, aminoglycoside
resistance genes are in yellow, the streptothricin resistance gene (sat4) is in blue, the tetracycline resistance gene [tet(O)] is in purple, genes with predicted
functions are in green, and genes coding hypothetical proteins are in white. The tet(O) gene is intact in types V and VI but is truncated in other types. The border
genes of theMDRGIs are depicted by black box arrows. The gray shading indicates regions sharingmore than 98%DNA identity. A representative strain for each
type of MDRGIs is indicated on the right of the panel.
Wang et al.
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FIG 2 PFGE andMLST typing of 58 erm(B)-positiveC. coli isolates. STs 5923, 5943, 5946, 5948, 6073, 6074, and 6075 were newly designated in this study. SmaI
was used for PFGE. Provinces and cities include Shandong (SD), Ningxia (NX), Guangdong (GD), Henan (HN), and Shanghai (SH). Sources and host species
include swine (S), chicken (C), chicken carcasses (CC), duck (D), and human (H)., a clonal complex cannot be assigned.
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while the aac and aacA-aphD genes in types I to IV exhibited
nucleotide identity of 99.9%. The aad9 gene in types V andVI also
showed 99.8% nucleotide identity to the aad9 gene on pCG8245
in C. jejuni (AY701528) (28). The tetracycline resistance gene
tet(O) was intact in types V and VI but was truncated in the other
types of MDRGIs. Detailed information on the ORFs in types I to
VI is presented in Table S3 in the supplemental material. During
the investigation of the genetic environment of erm(B) in C179b
and in other seven C. coli isolates, in which the erm(B) gene was
chromosome borne but was not inserted between cadF and
CCO1582 or in the aac gene located between nfsB and cinA, the
primer-walking strategy used in this study was not successful de-
spite several attempts. Thus, the flanking regions of erm(B) in
these isolates are unknown.Whole-genome sequence analysis will
be needed to determine the exact location of the erm(B) insertion
in these isolates.
Although the identified MDGRIs vary in size, gene content,
and insertion sites on the chromosome (Fig. 1), they shared a
common origin of Gram-positive bacteria. The erm(B) gene
and its neighboring genes in theMDRGIs are either identical or
almost identical to their orthologs in Gram-positive bacteria,
including Streptococcus, Enterococcus, Clostridium, Listeria, and
Lactobacillus (see Table S3 in the supplemental material), imply-
ing that all erm(B)-carrying MDRGIs in Campylobacter were de-
rived from Gram-positive origins. How Campylobacter acquired
the MDGRIs from Gram-positive bacteria is unknown and re-
mains to be determined.
Molecular typing and phylogenetic analysis of the erm(B)-
carryingC. coli isolates.PFGE andMLSTwere used to type the 57
erm(B)-positive C. coli isolates plus the previously reported
erm(B)-carrying C. coli isolate ZC113. MLST generated 30 se-
quence types (STs), seven of which were newly designated in this
study (Fig. 2). All 30 STs except for eight singletons were clustered
into one clonal complex, CC828. Using a cutoff of 80% pattern
similarity, the erm(B)-positive C. coli isolates were clustered into
28 PFGE subtypes (Fig. 2). The PFGE results generally corre-
sponded to theMLST typing data, asmost isolates of the same STs
also appeared in the same PFGE subtypes. For instance, 4 isolates
of human origin had the same ST (1145) and PFGE type (T1).
Likewise, the 12 isolates from chicken carcasses, all belonged to ST
860 and could be clustered together at95% (P1 and P2) accord-
ing to the PFGE types (Fig. 2). Among the 75 humanC. coli isolates
examined in this study, 10 of them harbored the erm(B) gene and
all of themwere on chromosomalMDRGIs. These 10 isolates were
from hospitals in Shanghai (n 9, collected in 2011) and Henan
province (n 1, collected in 2007). Six of the 10 isolateswere from
pediatric patients (50 days to 6 years of age), while the others were
from adults (24 to 54 years of age). Notably, 5 of the human iso-
lates (4 from children and 1 from an adult) shared the same PFGE
type andMLST type (Fig. 2), and were all from Shanghai, suggest-
ing that this particular genotype was associated with an outbreak
in the area. It should be acknowledged that nine out of the 10
human erm(B)-positive isolates were from Shanghai, suggesting
that the true extent of erm(B) gene dissemination among humans
in China cannot be determined in this study. Interestingly, a hu-
man isolate (SH-CCD11C419) from Shanghai and swine isolates
(ZC113 and DZ50) from Shandong were clustered together by
PFGE and MLST, all of which belong to ST1625 and PFGE sub-
type (A) using a cutoff of 80% genetic similarity for PFGE (Fig. 2),
suggesting that they are clonal and suggesting the possibility of
zoonotic transmission of this clone.
Transfer of erm(B)-carryingMDRGIs betweenC. coli andC.
jejuni. Our previous study showed that the type I MDRGI from
ZC113 could be transferred to C. jejuni NCTC 11168 via natural
transformation (11). In this study, we examined five other types of
MDRGIs and found that they were also transferable from C. coli
isolates toC. jejuniNCTC11168 or 81-176 by natural transforma-
tion. Transfer of theMDRGIs to the transformants was confirmed
by long-range PCR. Six different amplicons of expected sizes, in-
cluding 12,210 bp, 8,927 bp, 8,281 bp, 8,384 bp, 9,660 bp, and
9,684 bp, were obtained from transformants 11168-type I, 81-
176-type II, 11168-type III, 11168-type IV, 81-176-type V, and
81-176-type VI, respectively (Table 2). The sequencing results
confirmed that the MDRGIs in the transformants were identical
to those in the six types of donors. All transformants exhibited
high-level resistance to erythromycin and clindamycin (Table 2),
consistent with the known function of erm(B) in conferring resis-
tance to macrolides, lincosamides, and streptogramin B (10, 29).
Although the transformation was done under laboratory condi-
tions, this finding is alarming, asCampylobacter is naturally trans-
formable, and transfer of erm(B) between C. coli and C. jejuni
could conceivably occur in natural environments, which would
pose a great concern for public health, as a large portion of human
campylobacteriosis is associated with C. jejuni (30, 31).
We also tried to transfer some of the erm(B)-carrying plasmids
by natural transformation and electroporation. However, both
methods failed to move the plasmids to recipient Campylobacter
strains (C. coli ATCC 33559 and C. jejuni NCTC 11168 and 81-
176). This could be due to the difficulty of geneticmanipulation of
Campylobacter, as transformation of Campylobacter with plasmid
DNA is less efficient than that with chromosomal DNA (32). Ad-
ditionally,most of the erm(B)-carrying plasmids were above 70 kb
in size (data not shown), which may limit the efficiency of trans-
formation. At present, it is unknown if these plasmids can be
transferred by conjugation. Despite the difficulty in transferring
the plasmids, we performed plasmid typing with the 24 C. coli
isolates harboring a plasmid-borne erm(B). The PCR and se-
quencing results revealed that 14 of them were typeable and be-
longed to four incompatibility (Inc) groups, including IncA/C
(isolates JW16, 10-13-6a, 10-33-66, TH119, and TH74), IncW
(isolates LWC2, LWD21, TH34, and DZ50), IncY (isolates DZB5,
10-5-18, and TH96), and IncFIA (isolates 10-7-1a and 10-7-1c).
TABLE 2 Antimicrobial susceptibility of Campylobacter transformants
carrying the six types of MDRGIs
Straina
MIC (g/ml)b
CIP ERY CLI GEN TET
NCTC 11168 	0.25 1 0.125 0.5 0.5
81–176 	0.25 0.5 0.25 0.25 128
11168-type I (ZC113) 	0.25 512 256 64 0.5
81–176-type II (DZB4) 	0.25 64 128 64 128
11168-type III (ZP-GX-8) 	0.25 128 512 64 0.25
11168-type IV (HN-CCD07046) 	0.25 128 256 64 0.25
81–176-type V (SH-CCD11C073) 	0.25 128 128 1 128
81–176-type VI (SH-CCD11C365) 	0.25 256 128 1 128
a The strains in parentheses indicate the donors carrying MDRGIs.
b CIP, ciprofloxacin; ERY, erythromycin; CLI, clindamycin; GEN, gentamicin; TET,
tetracycline.
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Ten of the 24 isolates were not typeable with the methods used in
this study.However, it should be noted that it is unknownwhether
these identified plasmid types belonged to the erm(B)-carrying
plasmids or to other plasmids, as a givenC. coli isolatemay contain
more than one plasmid. The detailed genetic features of the
erm(B)-carrying plasmids and their transfer mechanisms remain
to be determined in future studies.
The identification of multiple erm(B)-positive isolates in this
study reinforced the findings in our recent report (11) and indi-
cates that erm(B) has emerged and is disseminating in Campylo-
bacter. This finding is significant, as macrolides are the key antibi-
otic for clinical therapy ofCampylobacter infections and resistance
mediated by rRNA methylase was not identified until recently
(11). Previously identified macrolide resistance mechanisms in
Campylobacter involved 23S rRNAmutations in conjunction with
the function of the CmeABC efflux pump (33, 34). The 23S rRNA
mutations are well known for conferring high-level macrolide re-
sistance in Campylobacter (7), but resistance-conferring muta-
tions in 23S rRNA occur at low frequencies and incur a significant
fitness cost in the absence of antibiotic selection pressure (35),
contributing to the low prevalence of macrolide-resistantCampy-
lobacter. The contribution of erm(B) to macrolide resistance in
Campylobacter was shown in our recent report (11) and in this
study using the transformants, in which 23S rRNA mutations
were absent and erm(B) alone elevated the MICs up to 512 g/ml
(Table 2). The data from Table 2 and part of the data in Table 1
(for isolates with no 23S rRNAmutations) clearly show the signif-
icance of erm(B) in conferring high-level macrolide resistance in
Campylobacter. Interestingly, the presence of both 23S rRNAmu-
tation and erm(B) did not appear to show an additive effect on
resistance, as macrolide MICs of the isolates harboring both
mechanisms did not differ significantly (P 0.05) from those of
the isolates having only erm(B) (Table 1). The emergence of
erm(B) in Campylobacter will likely change the landscape of mac-
rolide resistance in Campylobacter, as this resistance determinant
is horizontally transferable and may not cause a fitness burden in
the organism. This possibility warrants further investigation.
In summary, this study reveals the presence of a horizontally
transferable erm(B) in multiple Campylobacter isolates from var-
ious sources. In 59% of the cases, erm(B) was carried on chromo-
somal MDRGIs, along with other antibiotic resistance determi-
nants. The MDRGIs thus confer resistance to multiple classes of
antibiotics, including macrolides, lincosamides, and aminoglyco-
sides. Additionally, all erm(B)-carrying isolates exhibited resis-
tance to fluoroquinolones and tetracycline (Table 1). Thus, the
erm(B)-positive isolates, regardless of the location of erm(B) (on
the chromosome or a plasmid) or their origin of isolation (from
human patients or farm animals), are resistant to all antibiotics
that are important for clinical treatment of campylobacteriosis.
The multidrug resistance phenotype of the erm(B)-positive iso-
lates underlines the need for enhanced efforts to curb their further
spread, as there will be limited options for clinical treatment of
human patients infected by these isolates.
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